Clinical Manufacture

Commercial Manufacture

Drug Product Fill & Finish

Development

Testing

Discovery

Antibody Drug Conjugates

Technologies & Platforms
WuXi PharmaTech Receives Honorable Mention at 2014 ISPE Facility of the Year Awards
Apr 07, 2014

SHANGHAI, April 7, 2014 — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D services company with operations in China and the United States, today announced that it has received an honorable mention award at the International Society for Pharmaceutical Engineering’s (ISPE) 2014 Facility of the Year Awards for the company’s recently completed cGMP cell-culture-based biologics production facility in Wuxi. These awards, sponsored by ISPE, were created to showcase the best of each year’s new, state-of-the-art pharmaceutical manufacturing facilities. WuXi is the first company in China to receive this honor.

The judging panel praised WuXi’s “very innovative step” of adopting end-to-end single-use technology at the recently completed mammalian-cell-culture-based plant. Such an approach is at the leading edge of Western production plants and makes the facility the most advanced of its type in China. The design and construction of the plant meet the most stringent requirements of Western biopharmaceutical manufacturers, the panel concluded.

WuXi incorporated into the plant two parallel upstream cell culture bioreactor lines, with flexible working volumes of 50L to 2,000L, and one downstream purification production line. This arrangement gives WuXi the capacity, flexibility and quality to handle even the most demanding production projects. The facility is designed to meet cGMP standards of the U.S., the EU and China and has been GMP-audited more than 10 times by global clients.

“We are pleased to receive this recognition for our state-of-the art biologics production facility in Wuxi city,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “This award is further evidence that our company maintains the highest standards of quality in everything we do. This facility is an integral part of WuXi’s CRO/CMO strategy of helping clients to develop and manufacture biologics in China for global markets.”

BACK